| Suggest |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > High Yield Investments |
|
Suggest - High Yield Investments
High yield investments are investment programs that offer more potential for gain, but at a hi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product gher risk. High yield investment programs or HYIPs work on one of the basic principles of inve ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in sting: the higher the risk, the greater the potential for gain. Some of the investors choose t lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. o invest a small amount of money in these high yield investment programs. This practice allows here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe them to take advantage of high returns by putting a small investment at risk. A major issue d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro faced by high yield investment programs is the involvement of a large amount of money placed a ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc t risk for a high potential gain. Many investors are looking for quick, substantial gains and easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi therefore, though they could start with a lower sum, they choose to invest all they can. These nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically investors calculate the maximum amount of money they can afford to put on risk in order to ta and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ke advantage of the high potential return. Some investors go as far as investing more than the ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi can afford, though this is not recommended. Another issue is that some of the high yield inv ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a estment programs are well-disguised fraudulent schemes that are designed to rip investors off. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod Such HYIPs are illegal. Therefore, it is recommended that investors do a thorough background cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin check of the group or person presenting the investment. While investigating, investors must al tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen so check if the investment company has insured the investments of its clients. This further es t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tablishes the credibility of the company. With HYIPs, another possibility is that they may no ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust t pay as well as anticipated or may not pay at all. Therefore, experienced and smart investors y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products prefer to put only that amount of money in HYIPs that they can afford to loose without major . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de consequences. To combat various issues related with high yield investment programs, experts a elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip dvise to diversify the investment portfolio, as there is no real way to cushion the investment tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How To Create Your Own Products for Maximum Profits Keyword Perspective – Avoid This Mistake At All Cost
|